ArticleScientific reports2026
Integrating single-cell and bulk transcriptomes identifies B cell features associated with neoadjuvant chemoradiotherapy sensitivity in rectal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Neoadjuvant chemoradiotherapy (nCRT) is the main treatment for Locally Advanced Rectal Cancer (LARC). The response to nCRT varies from a complete response to no response. The impact of the B cells in this process is poorly understood. This study aimed to characterize the B cells types associated with response or resistance to nCRT. We applied the "Scissor" algorithm to integrate single-cell RNA-seq data with bulk transcriptome data from colorectal cancer samples, thereby identifying B cell subpopulations associated with nCRT response and exploring the clinical significance of B cell-related characteristic genes in nCRT for rectal cancer. At the single-cell level, we identified a B cell subpopulation characterized by the expression of HLA-DRB5, HLA-DQA2, HLA-DQB1, CD74, and ACTG1, which was associated with nCRT response in rectal cancer. Using subpopulation-specific trait genes, rectal cancer patients were classified into three distinct subtypes with unique features. Subtype A shows higher PD-L1 expression suggesting that patients in this subgroup are more likely to achieve favorable responses to immunotherapy. Subtype C shows lower hypoxia scores and a higher proportion of patients deriving clinical benefit from nCRT, suggesting that this subgroup may be more sensitive to neoadjuvant treatment. We developed a machine learning-based predictive model for pathological complete response (pCR) to nCRT in rectal cancer, achieving an area under the curve (AUC) of 0.911 in the training set and 0.819 in the 64-sample validation cohort. This study reveals that a B cell subpopulation characterized by the co-expression of HLA-DRB5, HLA-DQA2, HLA-DQB1, CD74, and ACTG1 is significantly associated with nCRT response in rectal cancer. These findings offer actionable insights for optimizing clinical treatment strategies, including patient stratification and personalized therapy selection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.